Adult: Initially, 100-400 mg daily in 2 divided doses, adjust according to response. Duration of therapy: 3-6 mth.
Oral Hereditary angioedema
Adult: Initially, 200 mg bid or tid. After an initial response is obtained, reduce by ≤50% at intervals of 1-3 mth or longer depending on the frequency of attack prior to initiation; if an attack occurs during treatment, may increase by up to 200 mg daily.
Adult: 200-800 mg daily in 2-4 divided doses, adjust according to response. Duration of treatment: 3-6 mth, up to 9 mth if necessary.
May be taken with or without food. Take consistently either always w/ or always w/o meals.
Undiagnosed abnormal genital bleeding, androgen-dependent tumour, thromboembolic disease or history of thrombosis, severe cardiac impairment. Severe hepatic and renal impairment. Pregnancy and lactation.
Patient w/ epilepsy, migraine, DM, polycythaemia, HTN and other CV disease, porphyria, lipoprotein disorder. Hepatic or renal impairment.
Perform LFT and renal function test periodically. Monitor haematologic parameters, lipid panel, signs and symptoms of intracranial HTN, androgenic changes, and/or fluid retention.
May prolong prothrombin time when used w/ warfarin. May increase serum concentrations of carbamazepine, ciclosporin, tacrolimus. Increased risk of myopathy and rhabdomyolysis when concurrently administered w/ statins (e.g. simvastatin, atorvastatin, lovastatin). May increase calcaemic response to synthetic vit D analogs. May cause insulin resistance.
Food, particularly high-fat meal, increases plasma concentration and extent of availability.
May interfere w/ determination of testosterone, androstenedione, dehydroepiandrosterone or plasma proteins.
Description: Danazol is an antigonadotropic agent which suppresses the pituitary-ovarian axis by inhibiting the pituitary output of FSH and LH, resulting in regression and atrophy of normal and ectopic endometrial tissue. It decreases growth rate of abnormal breast tissues, and also reduces attacks in hereditary angioedema by increasing C4 levels of the complement system. Onset: Benign breast disorder: 1 mth (pain relief); 4-6 mth (nodule elimination). Pharmacokinetics: Absorption: Absorbed from in the GI tract. Increased absorption w/ food. Time to peak plasma concentration: 4 hr. Metabolism: Extensively metabolised in the liver to 2-hydroxymethyl danazol and ethisterone. Excretion: Via urine and faeces. Elimination half-life: Approx 10 hr.
G03XA01 - danazol ; Belongs to the class of antigonadotropins and similar agents.
Anon. Danazol. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 19/09/2016.Buckingham R (ed). Danazol. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com . Accessed 19/09/2016.Danazol Capsule (Teva Pharmaceuticals USA, Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 19/09/2016.Joint Formulary Committee. Danazol. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 19/09/2016.McEvoy GK, Snow EK, Miller J et al (eds). Danazol. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 19/09/2016.